Dave Murdoch
Director of Corporate Communications
774.405.5719
david.murdoch@us.sumitomo-pharma.com
Thomas Hill
VP, Head of Corporate Communications
and Employee Engagement
949.239.3598
thomas.hill@us.sumitomo-pharma.com
News Releases
Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 5, 2025
MONTREAL and MARLBOROUGH, Mass., June 5, 2025 – Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. (“SMPA”
-
Apr 29, 2025
– Data include results from COURAGE Phase 3 and COMPOSUR Phase 4 studies of vibegron (GEMTESA®) – MARLBOROUGH, Mass., April 29, 2025 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA)...
-
Apr 15, 2025
– Data includes extension study results for vibegron in patients with overactive bladder (OAB) while being pharmacologically treated for benign prostatic hyperplasia (BPH), and real-world...
-
Apr 14, 2025
– Partnership with the NCI will build on the promising preliminary clinical activity of enzomenib in acute leukemia to further explore potential activity in other cancers – MARLBOROUGH, Mass.,...
-
Dec 23, 2024
– GEMTESA® is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH – MARLBOROUGH, Mass., Dec. 23, 2024...